WEGOVY® FLEXTOUCH® 0.5mg (Italian)

WEGOVY® FLEXTOUCH® 0.5mg is a dose-escalation stage in the Wegovy (semaglutide) treatment plan for chronic weight management in adults with obesity or overweight-related health risks. It is the second step in the four-dose escalation process designed to improve tolerability of the medication and optimize weight loss outcomes.

Semaglutide works by mimicking the GLP-1 hormone, which helps regulate appetite and food intake. This once-weekly subcutaneous injection promotes satiety, reduces caloric intake, and contributes to clinically significant weight loss when combined with a reduced-calorie diet and increased physical activity.

The 0.5mg dose is administered after completing four weeks at 0.25mg. Patients should continue taking 0.5mg once weekly for four additional weeks before moving on to higher doses.

• Dose: 0.5 mg semaglutide per 0.5 mL

• Duration at this dose: 4 weeks

• Administration frequency: Once weekly, on the same day each week

• Administration route: Subcutaneous (abdomen, thigh, or upper arm)

• Device: FlexTouch® pre-filled single-use pen

• Includes needle: Yes (NovoFine® Plus, 32G, 4mm)

• Injection timing: With or without food, any time of day

WEGOVY® is indicated for the treatment of adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.

Contraindications:

• History or family history of medullary thyroid carcinoma (MTC)

• Presence of MEN2 (Multiple Endocrine Neoplasia syndrome type 2)

• Hypersensitivity to semaglutide or formulation components

• Use during pregnancy or breastfeeding not recommended

Side Effects:

• Very common: Nausea, vomiting, diarrhea, constipation

• Common: Abdominal pain, headache, fatigue

• Occasional: Bloating, dyspepsia, dizziness

• Serious risks: Pancreatitis, cholelithiasis, kidney dysfunction in dehydrated patients

• Black box warning: Thyroid C-cell tumors (in animal studies)

Each 0.5 mL injection contains 0.5 mg of semaglutide, a modified GLP-1 analog engineered for extended activity and metabolic stability.

• Active ingredient: Semaglutide 0.5 mg per 0.5 mL

• Excipients:

  • Disodium phosphate dihydrate

  • Sodium chloride

  • Hydrochloric acid/sodium hydroxide (for pH adjustment)

  • Water for injections

• Appearance: Clear, colorless to slightly yellow solution

Each retail carton contains a one-month supply of medication, designed for ease of self-administration and dose consistency.

• 4 pre-filled single-use pens, each delivering 0.5 mg semaglutide in 0.5 mL

• 4 disposable NovoFine® Plus needles (32G x 4mm)

• Instructions for Use leaflet included

• Each pen is preassembled and ready to use, no priming required

Most side effects are related to the gastrointestinal system, especially during the early dose-escalation stages. These effects often diminish with continued use and proper patient guidance.

• Common: Nausea, vomiting, diarrhea, constipation

• Occasional: Headache, fatigue, dizziness, dyspepsia

• Serious: Acute pancreatitis, gallbladder disease, acute kidney injury (in dehydration)

• Rare: Thyroid C-cell tumors (seen in animal studies)

• Patients should be advised to stay hydrated and report persistent or severe symptoms

Proper cold storage is essential for maintaining the potency and sterility of semaglutide. Opened and unopened pens should be handled according to the following conditions:

• Unopened pens: Store in refrigerator (2°C to 8°C)

• Opened pens: May be stored at room temperature (up to 30°C) for a maximum of 6 weeks

• Do not freeze

• Protect from light and heat sources

• Keep pens capped and discard if expired or frozen